AtriCure Executive and Leadership Team

Michael Carrel, the President & Chief Executive Officer at AtriCure, directs the overarching strategic vision for the organization. By prioritizing the development of innovative technologies for the treatment of Atrial Fibrillation, the President & Chief Executive Officer ensures the company maintains a competitive edge in the medical device sector. Carrel oversees the alignment of research initiatives with long-term commercial objectives, fostering a culture of clinical excellence. Through the management of high-level board relations and investor communications, the President & Chief Executive Officer drives the expansion of market reach across North American and international territories. Michael Carrel monitors the execution of corporate goals, ensuring that every operational milestone supports the mission of improving patient outcomes. This leadership role requires constant evaluation of the competitive landscape to secure sustainable growth and maintain the reputation of the firm as a leader in cardiovascular health solutions.

Angela Wirick, the Chief Financial Officer at AtriCure, manages the fiscal health and capital allocation strategies of the organization. Overseeing financial planning, reporting, and treasury functions, the Chief Financial Officer ensures the company possesses the necessary resources to support ongoing research and development of Atrial Fibrillation treatments. Wirick directs the budgeting process, providing critical insights to the executive team regarding market performance and operational efficiency. By maintaining rigorous internal controls and transparency, the Chief Financial Officer safeguards the financial integrity of the firm during periods of global expansion. Angela Wirick coordinates with external stakeholders to communicate the value proposition of the company, driving investor confidence through disciplined fiscal management. This role involves analyzing complex economic data to mitigate risks while identifying opportunities for investment in emerging medical technologies that align with the core mission of the business.

Douglas Seith, the Chief Operating Officer at AtriCure, executes the daily operational strategies required to deliver medical technologies to a global patient base. Overseeing supply chain logistics, manufacturing quality, and commercial distribution, the Chief Operating Officer ensures seamless delivery of products used in the treatment of Atrial Fibrillation. Seith directs the cross-functional teams responsible for scaling production to meet rising demand in international markets. By optimizing internal processes, the Chief Operating Officer improves operational efficiency and reduces time-to-market for new clinical solutions. Douglas Seith monitors performance metrics across all departments, ensuring that operational output aligns with the strategic goals established by the executive leadership team. This role involves managing complex logistical networks to maintain high service levels for healthcare facilities, ultimately supporting the mission of the company by ensuring that life-saving technologies reach the clinicians who need them most.

Salvatore Privitera, the Chief Technology Officer at AtriCure, architects the technical roadmap for the development of advanced medical devices. By leading the engineering and research teams, the Chief Technology Officer drives the creation of innovative solutions designed to address the complexities of Atrial Fibrillation. Privitera oversees the entire product lifecycle, from initial conceptualization to final clinical validation, ensuring that every device meets the highest standards of safety and efficacy. The Chief Technology Officer collaborates with clinical experts to integrate cutting-edge science into practical, scalable manufacturing processes. Salvatore Privitera manages the intellectual property portfolio, protecting the technological advancements that define the market position of the company. Through the continuous evaluation of emerging trends in medical engineering, the Chief Technology Officer ensures the firm remains at the forefront of cardiovascular innovation, delivering superior tools to surgeons and healthcare providers across global markets.